Harrow Health, Inc. (HROW) AI Stock Analysis

Harrow Health, Inc. specializes in the healthcare sector with a focus on ophthalmology. The company operates ImprimisRx, an arm dedicated to ophthalmic outsourcing and pharmaceutical compounding that supplies specialized formulations to eye care practitioners and patients. Its product lineup includes DEXYCU, an innovative solution for treating post-operative inflammation. Harrow Health also maintains equity interests in Surface Ophthalmics, Inc., Melt Pharmaceuticals, Inc., and commercial-stage Eton Pharmaceuticals, Inc. In addition, the company owns royalty rights in four clinical-stage drug candidates under development by Surface Ophthalmics and Melt Pharmaceuticals. Founded in 2006, the company is headquartered in San Diego, California, and employs 373 people.

Harrow Health grew annual revenue from $72.5M in FY2021 to $272.3M in FY2025, recording a 5-year revenue CAGR of 41.0%. In FY2025, revenue increased 36.4%, with gross margin reaching 75.1% and operating margin expanding to 14.2%. Net income improved to -$5.1M in FY2025 from -$17.5M in FY2024. For the trailing twelve months ended June 30, 2026, revenue stood at $275.6M with an operating margin of -15.6% and EPS of -$0.99. In the latest quarter, revenue grew 10.9% year-over-year, while earnings declined 10.3%.

As of June 30, 2026, Harrow Health held $83.9M in cash and short-term investments against total debt of $300.7M, resulting in net debt of $216.9M. Total assets were $416.8M, compared to shareholders' equity of $15.2M, which yields a debt-to-equity ratio of 19.79. The company closed the quarter with a current ratio of 2.24. In FY2025, operating cash flow turned positive at $43.9M, free cash flow reached $42.8M, and capital expenditures were $1.1M.

Harrow Health trades at an enterprise value of $1.48B and a market cap of $1.02B at its last close of $27.28. Its forward P/E of 46.7x trades at a premium to the 17.3x median of its US-listed Healthcare peers. Its EV to EBITDA stands at 129.8x versus the peer median of 12.0x, while its price-to-sales ratio of 3.7x is slightly below the peer median of 4.1x. Over the past year, HROW shares declined 28.1%, underperforming the S&P 500 return of 16.8%.

Consensus coverage includes 9 Strong Buy ratings, with zero Buy, Hold, Sell, or Strong Sell ratings. The mean price target is $65.00, which sits 138.3% above the last close of $27.28. For the fiscal year ending December 31, 2026, analysts estimate revenue of $350.1M and EPS of $0.43. Over the last four quarters, Harrow Health has beaten EPS estimates in 1 quarter. The next earnings date is scheduled for November 9, 2026.

This page is an AI-written research summary of Harrow Health, Inc. (HROW). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: HROW income statement, HROW balance sheet, HROW key metrics, HROW analyst forecast, HROW chart. See the HROW stock overview for the latest quote and news.